Centre hospitalier universitaire de Limoges

Their core work

CHU Limoges is a French university teaching hospital that combines patient care with clinical research, particularly in severe infections, sepsis, and advanced cell-based therapies. Its teams run clinical trials in hospital settings, contributing patient recruitment capacity, ICU and infectious disease expertise, and clinical data to multi-country medical research consortia. It acts as both a clinical investigation site and a scientific contributor, bridging laboratory research and real-world hospital practice in central-western France.

What they specialise in

How they've shifted over time

Between 2015 and 2020 the hospital's H2020 work centred on a single but ambitious clinical trial (SEPCELL) applying adipose-derived allogeneic stem cells to severe community-acquired pneumonia and sepsis — a regenerative medicine bet. From 2021 onwards the focus pivoted away from experimental cell therapy toward broad infectious-disease clinical research infrastructure through ECRAID-Base, covering outbreak preparedness and antimicrobial resistance. The trajectory is a clear move from a niche cell-therapy trial toward permanent embedding in Europe's infectious-disease clinical trial network.

CHU Limoges is moving toward long-term participation in European clinical research infrastructure for infectious diseases, AMR, and pandemic preparedness — a good fit for consortia needing a reliable French clinical site.

How they like to work

The hospital joins as a participant rather than coordinator and has worked inside sizeable consortia — 25 unique partners across 9 countries in just two projects. Its role is that of a clinical contributor inside multi-country medical trials, not a scientific lead. Partners can expect disciplined trial execution and patient access rather than consortium-level project management.

25 consortium partners across 9 countries, reached through only two projects — a fairly dense European medical network relative to its project count, with partners spread across EU health research hubs rather than concentrated in one region.

What sets them apart

CHU Limoges combines a regional French university hospital's clinical trial capacity with a track record in two very different but high-value health domains: advanced cell therapy trials and pan-European infectious disease research. Its value to a consortium is access to an ICU-equipped teaching hospital with experience running both complex ATMP trials and rapid-response infectious disease studies. For partners, it is a dependable clinical site outside the usual Paris-Lyon axis, useful for geographic diversity in French patient recruitment.

Highlights from their portfolio

• SEPCELL
  A complex clinical trial of allogeneic adipose-derived stem cells in severe community-acquired pneumonia — a high-risk ATMP study rather than routine hospital research.
• ECRAID-Base
  Places the hospital inside Europe's permanent infrastructure for infectious disease clinical trials, AMR research, and outbreak response — its largest H2020 grant at EUR 2.39M.